Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Nestle shuts Swiss...

    Nestle shuts Swiss skin health products factory

    Written by Ruby Khatun Khatun Published On 2017-09-04T09:15:57+05:30  |  Updated On 4 Sept 2017 9:15 AM IST
    Nestle shuts Swiss skin health products factory

    ZURICH: Nestle said on Thursday it was closing a Swiss factory which makes products for its skin health business, responding to a slowdown in a business once seen as one of its rising stars.


    Nestle Skin Health said it will close the Egerkingen factory in northern Switzerland, where it makes Daylong sun cream and products for dry skin, with the loss of 190 jobs.


    Skin health has been part of the food maker’s push into higher growth and more profitable health products to counter a slowdown in its traditional packaged food business.


    The business was set up in 2014 when Nestle incorporated the half stake in skin care company Galderma it bought from L‘Oreal with the half it already owned.


    Nestle does not break out results for its skin health business separately but said in July the business had lower sales volumes and pricing during the second quarter of this year as pressure on generics in the prescription business weighed on growth as did China’s soft performance.


    Patrik Schwendimann, an analyst at Zuercher Kantonalbank, estimates that Nestle’s Skin Health Business had sales of roughly 2.3 billion Swiss francs ($2.38 billion) last year, up from 2.2 billion francs a year earlier. Profit margins for skin health and Nestle Health Science combined were around 9.2 percent last year, down from 12.5 percent in 2015.


    “The business is still in the expansion phase, but the results have been disappointing,” said Schwendimann. “They are aiming for higher margins and higher sales growth especially when companies in the health area should be getting margins of at least 15 to 20 percent in the mid term.”


    Nestle has responded by launching an overhaul of its skin health business where it aims to simplify its organization and its geographical footprint.


    The company currently sells dozens of different products via prescription, over the counter and as corrective and aesthetic products which are used by doctors.


    Nestle said production costs at the Egerkingen site had been rising because volumes were low and the factory was not running at full capacity.


    “Nestle Skin Health does not foresee a significant volume increase over the next years in Egerkingen, even taking into account growth forecasts for markets served by the factory,” the company said.


    Production will be transferred to other Nestle skin health factories, with its commercial business for Switzerland moved to Zurich and its team in consumer products development moved to the Swiss canton of Vaud.




    (Reporting by John Revill, editing by David Evans)



    Daylong sun creamdry skinEgerkingen factoryfactoryGaldermaL'OrealNestlePatrik Schwendimannproductsshutsskin healthskin health businessslowdownSwiss
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok